Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors

Digestive Diseases and Sciences

Volumn 51, Issue 5, 2006, Pages 877-884

  Clancy, Thomas E ^a   Sengupta, Tanya P ^b   Paulus, Jessica ^b   Ahmed, Fawzia ^c   Duh, Mei Sheng ^c   Kulke, Matthew H ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c ANALYSIS GROUP   (United States)

Author keywords

Alkaline phosphatase; Carcinoid tumor; Chromogranin; Neuroendocrine tumor; Prognostic factor; Survival

Indexed keywords

ALKALINE PHOSPHATASE;

ADULT; ARTICLE; ARTIFICIAL EMBOLISM; CANCER SURVIVAL; CARCINOID; CRYOTHERAPY; FEMALE; HUMAN; KAPLAN MEIER METHOD; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEUROENDOCRINE TUMOR; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RADIOFREQUENCY ABLATION; TREATMENT OUTCOME; TUMOR DIAGNOSIS;

ALKALINE PHOSPHATASE; ANALYSIS OF VARIANCE; BILIRUBIN; CARCINOID TUMOR; FEMALE; HUMANS; INTESTINAL NEOPLASMS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SOMATOSTATINOMA; SURVIVAL ANALYSIS;

EID: 33745854466     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-006-9345-4     Document Type: Article

References (33)

1. Yu F, Venzon DJ, Serrano J, et al.: Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol 17(2):615-630, 1999 (available at: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd= Retrieve&db=PubMed&dopt=Citatio& list_uids=10080607)
2. Clements D, Elias E: Regression of metastatic vipoma with somatostatin analogue SMS 201-995. Lancet 1(8433):874-875, 1985 (available at: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list_uids=2858733)
3. Frank M, Klose KJ, Wied M, Ishaque N, Schade-Brittinger C, Arnold R: Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol 94(5):1381-1387, 1999 (available at: http://www.ncbi.nlm.nih.gov/entrez/query. fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10235222)
4. Arnold R, Neuhaus C, Benning R, et al.: Somatostatin analog sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors. World J Surg 17(4):511-518, 1993 (available at: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citatio& list_uids=8395752)
5. Saltz L, Trochanowski B, Buckley M, et al.: Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer 72(1):244-248, 1993 (available at: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list_uids=8389666)
6. Arnold R, Trautmann ME, Creutzfeldt W, et al.: Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 38(3):430-438, 1996 (available at: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list_uids=8675099)
7. Faiss S, Pape UF, Bohmig M, et al.: Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21(14):2689-2696, 2003 (available at: http://www.ncbi.nlm.nih.gov/entrez/ query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12860945)
8. Faiss S, Rath U, Mansmann U, et al.: Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors. Digestion 60(5):469-476, 1999 (available at: http://www.ncbi.nlm.nih.gov/entrez/ query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10473972)
9. Chu QD, Hill HC, Douglass HO Jr, et al.: Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas. Ann Surg Oncol 9(9):855-862, 2002 (available at: http://www.ncbi.nlm.nih.gov/ entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids= 12417506)
10. Harpole DH Jr, Feldman JM, Buchanan S, Young WG, Wolfe WG: Bronchial carcinoid tumors: a retrospective analysis of 126 patients. Ann Thorac Surg 54(1):50-54, discussion 54-55, 1992 (available at: http://www.ncbi.nlm.nih.gov/ entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids= 1610254)
11. Nobels FR, Kwekkeboom DJ, Bouillon R, Lamberts SW: Chromogranin A: its clinical value as marker of neuroendocrine tumours. Eur J Clin Invest 28(6):431-440, 1998 (available at: http://www.ncbi.nlm.nih.gov/entrez/query. fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9693933)
12. O'Connor DT, Deftos LJ: Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med 314(18):1145-1551, 1986 (available at: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list_uids=3007986)
13. Bajetta E, Ferrari L, Martinetti A, et al.: Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 86(5):858-865, 1999 (available at: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd= Retrieve&!db=PubMed&dopt=Citation&list_uids=10463986)
14. Baudin E, Gigliotti A, Ducreux M, et al.: Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer 78(8):1102-1107, 1998 (available at: http://www.ncbi.nlm.nih.gov/entrez/query. fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9792158)
15. Seregni E, Ferrari L, Bajetta E, Martinetti A, Bombardieri E: Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Ann Oncol 12 (Suppl 2):S69-S72, 2001 (available at: http://www.ncbi.nlm.nih.gov/ entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids= 11762355)
16. Stridsberg M, Oberg K, Li Q, Engstrom U, Lundqvist G: Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol 144(1):49-58, 1995 (available at: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list_uids=7891024)
17. Weber HC, Venzon DJ, Lin JT, et al.: Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 108(6):1637-1648, 1995 (available at: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list_uids=7768367)
18. Nobels FR, Kwekkeboom DJ, Coopmans W, et al.: Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 82(8):2622-2628, 1997 (available at: http://www.ncbi.nlm.nih.gov/entrez/query. fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9253344)
19. Janson ET, Holmberg L, Stridsberg M, et al.: Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 8(7):685-690, 1997 (available at: http://www.ncbi.nlm.nih.gov/entrez/ query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9296223)
20. Hsiao RJ, Seeger RC, Yu AL, O'Connor DT: Chromogranin A in children with neuroblastoma. Serum concentration parallels disease stage and predicts survival. J Clin Invest 85(5):1555-1558, 1990 (available at: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list_uids=2332506)
21. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG: Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 197(1):29-37, 2003 (available at: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list_uids=12831921)
22. Grama D, Eriksson B, Martensson H, et al.: Clinical characteristics, treatment and survival in patients with pancreatic tumors causing hormonal syndromes. World J Surg 16(4):632-638. 1992 (available at: http://www.ncbi.nlm. nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt= Citation&list_uids=1357829)
23. Moinuddin M, Dean P, Vander Zwaag R, Dragutsky M: The limitation of liver function tests in metastatic carcinoid tumors. Cancer 59(7):1304-1306, 1987 (available at: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd= Retrieve&db=PubMed&dopt=Citation&list_uids=3545433)
24. Lahr CJ, Soong SJ, Cloud G, Smith JW, Urist MM, Balch CM: A multifactorial analysis of prognostic factors in patients with liver metastases from colorectal carcinoma. J Clin Oncol 1(11):720-726, 1983 (available at: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list_uids=6668490)
25. Eriksson B, Oberg K, Stridsberg M: Tumor markers in neuroendocrine tumors. Digestion 62(Suppl 1):33-38, 2000 (available at:http://www.ncbi.nlm.nih. gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation& list_uids=10940685)
26. Taupenot L, Harper KL, O'Connor DT: The chromogranin-secretogranin family. N Engl J Med 348(12):1134-1148, 2003 (available at: http://www.ncbi.nlm. nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt= Citation&list_uids=12646671)
27. Broughan TA, Leslie JD, Soto JM, Hermann RE: Pancreatic islet cell tumors. Surgery 99(6):671-678, 1986 (available at: http://www.ncbi.nlm.nih.gov/ entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids= 2424108)
28. Lo CY, van Heerden JA, Thompson GB, Grant CS, Soreide JA, Harmsen WS: Islet cell carcinoma of the pancreas. World J Surg 20(7):878-883, discussion 884, 1996 (available at:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd= Retrieve&db=PubMed&dopt=Citation&list_uids=8678966)
29. White TJ, Edney JA, Thompson JS, Karrer FW, Moor BJ: Is there a prognostic difference between functional and nonfunctional islet cell tumors? Am J Surg 168(6):627-629, discussion 629-630, 1994 (available at:http://www.ncbi. nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt= Citation&list_uids=7978008)
30. Onaitis MW, Kirshbom PM, Hayward TZ, et al.: Gastrointestinal carcinoids: characterization by site of origin and hormone production. Ann Surg 232(4):549-556, 2000 (available at: http://www.ncbi.nlm.nih.gov/entrez/query. fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10998653)
31. Modlin IM, Sandor A: An analysis of 8305 cases of carcinoid tumors. Cancer 79(4):813-288, 1997 (available at:http://www.ncbi.nlm.nih.gov/entrez/ query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9024720)
32. Shebani KO, Souba WW, Finkelstein DM, et al.: Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg 229(6):815-821, discussion 822-823, 1999 (available at: http://www.ncbi.nlm.nih.gov/entrez/ query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10363895)
33. McDermott EW, Guduric B, Brennan MF: Prognostic variables in patients with gastrointestinal carcinoid tumours. Br J Surg 81(7):1007-1008, 1994 (available at:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db= PubMed&dopt=Citation&list_uids=7922047)